NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lantern Pharma Inc. (LTRN) Stock Analysis

Lantern Pharma Inc. (LTRN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LTRN

$0.68

+$0.03 (+4.28%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LTRN with… →

LTRN Key Statistics

As of Oct 21, 2026
Trading
Open
$0.67
Previous Close
$0.66
Day's Range
0.67–0.71
52-Week Range
0.60–4.34
Volume
115.57K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.32
Valuation
Market Cap
$10.22M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.63
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$17.12M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.94M
1-Year Return
−82.78%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
214.58K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LTRN closed at $0.68, −82.78% over 1 year.

Lantern Pharma Inc. (LTRN) has a market capitalization of $10.22M.

In fiscal 2025, LTRN reported revenue of $0.00.

LTRN Stock Return by Calendar Year

Lantern Pharma Inc. (LTRN) return since Jun 2020: what $10,000 became

1 year
$10,000 $1,722
−82.78%
5 years
$10,000 $663
−93.37%
Since Jun 2020
$10,000 $458
−95.42%

If you had invested $10,000 in Lantern Pharma Inc. (LTRN) at the close on June 11, 2020, the earliest close on record here, it would have been worth $458 at the close on October 21, 2026: −95.42% in total, −38.42% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−77.41%
2025−5.02%
2024−25.47%
2023−29.14%
2022−24.31%
2021−58.55%
2020 (partial year)+28.76%

As of October 21, 2026.

LTRN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$17.12M—
2024$0.00−$20.78M—
2023$0.00−$15.96M—
2022$0.00−$14.26M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$17.98M−$17.12M—
2024$0.00—−$22.22M−$20.78M—
2023$0.00—−$17.88M−$15.96M—
2022$0.00—−$14.43M−$14.26M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lantern Pharma Inc. (LTRN) is capitalised at $10.22M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 16 employees.

The most recent close on file for LTRN is $0.68, dated October 21, 2026. That is +$0.03 (+4.28%) against the previous close. The 52-week range on file runs from $0.60 to $4.34. The latest close sits 14.46% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $17.12M. Trailing earnings per share are −1.63.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.32. Daily returns over the trailing 6 years annualize to a volatility of 84.29%. The trailing one-year total return is −82.78%. Measured over 5 years, that is −41.89% a year compounded.

Growth & Income

No dividend is on file for LTRN.

2026 is still running; the total return is −77.41% year to date. Across the complete calendar years on file, 2025 returned −5.02% and 2021 returned −58.55%. Of the 5 complete calendar years on file, 0 finished higher.

Peer Comparison

Lantern Pharma Inc. (LTRN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lantern Pharma Inc. LTRN $10.22M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lantern Pharma Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lantern Pharma Inc.

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Visit website →